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Abstract 
Background: Patients with diabetes mellitus (DM) have an increased risk of developing heart failure (HF). Further, DM 
is associated with poor prognosis in patients with HF. Our aim was to determine whether DM has any impact on the 
predictive value of a multi‑biomarker panel in patients with HF.
Methods: We included 1069 consecutive ambulatory HF patients in the study: age 66.2 ± 12.8 years, 33.5 ± 13.3 
left ventricular ejection fraction, 36% diabetic patients. We measured serum concentrations of N‑terminal pro‑brain 
natriuretic peptide (NT‑proBNP), high‑sensitivity troponin T (hs‑TnT), ST2, galectin‑3, high‑sensitivity C reactive protein 
(hs‑CRP), cystatin‑C, soluble transferrin receptor (sTfR), and neprilysin and followed patients for 4.9 ± 2.8 years. Primary 
endpoints were all‑cause and cardiovascular death.
Results: During follow‑up, 534 patients died; 283 died of cardiovascular causes. Diabetic subjects had higher mortal‑
ity (57.7 vs. 45.6%, p < 0.001). NTproBNP (p = 0.07), hs‑TnT (p < 0.001), galectin‑3 (p < 0.001), and cystatin‑C (p = 0.001) 
concentrations were higher in diabetic patients, whereas sTfR levels were lower (p = 0.005). There were no interac‑
tions between DM and NTproBNP, hs‑TnT, galectin‑3, hs‑CRP, cystatin‑C, sTfR, and neprilysin relative to risk prediction 
for all‑cause or cardiovascular death. By contrast, ST2 significantly interacted with DM for all‑cause (p = 0.02) and 
cardiovascular (p = 0.03) death. In diabetic patients, HRs for ST2 were 1.27 (95% CI 1.16–1.40, p < 0.001) and 1.23 
(95% CI 1.09–1.39, p = 0.001) for all‑cause and cardiovascular death, respectively. In nondiabetic patients, HRs for ST2 
were 1.53 (95% CI 1.35–1.73, p < 0.001) and 1.64 (95% CI 1.31–2.05, p < 0.001) for all‑cause and cardiovascular death, 
respectively. The multivariable Cox regression analysis showed that hs‑TnT and ST2 were the only markers that were 
independently associated with both all‑cause and cardiovascular mortality in patients with HF and diabetes. Moreo‑
ver, in these patients, the combination of these two markers significantly increased discrimination as assessed by the 
area under the curve.
Conclusions: Biomarkers used in the general population to predict the clinical course of heart failure are also useful 
in patients with diabetes. In these patients, among all the biomarkers analysed only hs‑TnT and ST2 were indepen‑
dently associated with both all‑cause and cardiovascular mortality.
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Background
Epidemiological studies have confirmed that the presence 
of diabetes mellitus (DM) is associated with an increased 
risk of developing heart failure (HF) [1, 2]. Indeed, HF is 
often the first cardiovascular manifestation observed in 
diabetic patients [3]. The increased risk of HF persists 
even after adjustment for confounders such as coro-
nary artery disease and hypertension. Further, diabetic 
patients with HF have a poor prognosis [4].
It is challenging to stratify risk for patients with HF. 
Established risk factors such as left ventricular ejection 
fraction (LVEF), New York Heart Association (NYHA) 
functional class, comorbidities (DM, anemia, and renal 
insufficiency), and treatment strategies do not fully 
explain the mortality risk associated with HF patients [5–
7]. Prognostication may be refined by measurement of 
biomarkers for different pathophysiological processes not 
reflected by established mortality risk factors [8] Circu-
lating biomarkers measured in patients with HF are clas-
sified into seven pathophysiological pathways, including 
myocardial stretch, myocyte injury, extracellular matrix, 
inflammation, renal dysfunction, neurohormonal activa-
tion, and oxidative stress [9, 10]. In recent years, there is 
a growing interest in relation to the clinical usefulness of 
these biomarkers in patients with diabetes [11] as well as 
to their pathogenic role in the development of vasculopa-
thy [12, 13]. Some of these biomarkers have been shown 
to be associated with the risk of diabetes [14–16] and 
their serum levels were described to be modified by med-
ical treatment [17]. It is unclear whether systemic dis-
eases such as DM may affect the predictive value of these 
HF biomarkers. Accordingly, our aim in the present study 
was to assess whether DM had any impact on the pre-
dictive value of a multi-biomarker panel in patients with 
HF. We included the following biomarkers: N-terminal 
pro-brain natriuretic peptide (NT-proBNP; myocardial 
stretch and neurohormonal activation), neprilysin (neu-
rohormonal activation), galectin-3 (extracellular matrix), 
ST2 (inflammation, stretch, and extracellular matrix), 
high-sensitivity troponin T (hs-TnT; myocardial injury), 
cystatin-C (renal dysfunction), high-sensitivity C reactive 
protein (hs-CRP; inflammation), and soluble transferrin 
receptor (sTfR; oxidative stress).
Methods
Study population
The present study is a subanalysis of a previous investi-
gation of the performance of different biomarkers in a 
well-established HF cohort [10–13]. From May 2006 to 
2013, ambulatory patients treated at a multidisciplinary 
HF clinic were consecutively included in the study. Refer-
ral inclusion criteria and blood sample collection are 
described elsewhere [4–7]. All analyses of biomarkers 
were performed on the same blood sample, which had 
been stored at −80° without prior freeze–thaw cycles. All 
samples were obtained between 9:00 a.m. and 12:00 p.m. 
Serum concentrations of NT-proBNP (N  =  1030), hs-
TnT (N  =  803), ST2 (N  =  814), galectin-3 (N  =  811), 
hs-CRP (N = 773 after we excluded 16 patients with lev-
els ≥100 mg/dL), cystatin-C (N = 804), STfR (N = 794), 
and neprilysin (N = 1069) were measured.
All of the participants provided written informed con-
sent, and the local ethics committee approved the study. 
All of the study procedures were in accordance with the 
ethical standards outlined in the Helsinki Declaration of 
1975 (revised in 1983).
Follow‑up and outcomes
All patients made follow-up visits at regular, predefined 
intervals, and they made additional visits as required in 
cases of decompensation. The regular visitation sched-
ule included a minimum of quarterly visits with nurses; 
biannual visits with physicians; and elective visits with 
geriatricians, psychiatrists, and rehabilitation physicians. 
Patients who did not attend the regular visits were con-
tacted by telephone.
The primary outcomes of the present study were all-
cause and cardiovascular death. A death was considered 
cardiovascular in origin if it was caused by HF (decom-
pensated HF or treatment-resistant HF in the absence of 
another cause), sudden death (unexpected death, wit-
nessed or not, of a previously stable patient with no evi-
dence of worsening HF or any other cause of death), acute 
myocardial infarction (due to mechanical, haemodynamic, 
or arrhythmic complications), stroke (in association with 
recent acute neurological deficits), procedural (death after 
diagnostic or therapeutic procedures), and other cardio-
vascular causes (e.g., rupture of an aneurysm, peripheral 
ischaemia, or aortic dissection). Fatal events were identi-
fied from paper and electronic clinical records, from gen-
eral practitioners, and by contacting the patients’ relatives. 
Data were verified by comparisons with the databases of 
the Catalan and Spanish health systems. Events were adju-
dicated by two of the authors (MD and JL). Follow-up was 
closed on 30 September 2015. Five patients were lost dur-
ing follow-up and appropriately censored.
DM diagnosis
A diagnosis of DM was made when one of the follow-
ing criteria were met: (1) a diagnosis of DM was previ-
ously established and recorded in the patient’s electronic 
history, (2) fasting plasma glucose  ≥126  mg/dL or 
HbA1c ≥6.5% identified by laboratory testing [18], or (3) 
the patient had a current prescription for oral hypogly-
caemic medication or insulin. All the included patients in 
this study had type 2 diabetes.
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NTproBNP assay
NTproBNP levels were determined by an immunoelec-
trochemiluminescence method (Elecsys®; Roche Diag-
nostics, Switzerland). The assay had inter-run CVs of 
0.9–5.5%.
Hs‑TnT assay
Hs-TnT levels were measured by electrochemilumines-
cence immunoassay on the Modular Analytics E 170 
(Roche Diagnostics). The hs-TnT assay had an analytic 
range of 3–10,000  ng/L. At the 99th percentile value of 
13 ng/L, the CV was 9%.
ST2 assay
ST2 levels were measured from plasma samples with 
a high-sensitivity sandwich monoclonal immunoassay 
(Presage® ST2 assay; Critical Diagnostics, San Diego, 
CA, USA). The ST2 assay had a within-run coefficient 
of <2.5% and total CV of 4%.
hsCRP assay
hsCRP concentrations were measured by particle-
enhanced turbidimetry (CRPHS, ref. 04628918 190; 
Roche Diagnostics) on the automatic analyser Cobas 
6000 (Roche Diagnostics). The linearity of the method 
was 0.15–20.0 mg/L, the detection limit was 0.15 mg/L, 
the functional sensitivity was 0.3 mg/L, and the interser-
ial CV was <8.4%.
Galectin‑3 assay
For galectin-3 measurements, we used an enzyme-linked 
fluorescent assay (BioMerieux ref. 411191) on a mini-
VIDAS® analyser (BioMerieux, France). The CV for the 
assay was <10%, the linearity was 3.3–100.0 ng/mL, and 
the limit of detection was 2.4 ng/mL.
Cystatin‑C assay
Cystatin C was measured by a nephelometric technique 
that assesses immune complex formation between cys-
tatin and antiserum anticystatin-C attached to latex 
particles (Cystatin C Radim, ref. NPP42; Radim Group, 
Pomezia, Italy). The CV between assays was 2.9%.
STfR assay
Soluble transferrin receptor concentrations were meas-
ured with a particle-enhanced turbidimetric immuno-
assay (Tina-quant Soluble Receptor Transferrin STFR, 
Roche Diagnostics) on the automatic analyser Cobas 
6000 (Roche Diagnostics). The linearity of the method 
was 0.5–40.0  mg/L, the detection limit was 0.50  mg/L, 
and the interserial CV was <3.8%.
Neprilysin assay
Human neprilysin (NEP) was measured with a modified 
sandwich immunoassay (HUMAN NEP/CD10 ELISA kit, 
ref. SK00724-01, lot no. 20111893; Aviscera Biosciences, 
Santa Clara, CA, USA). At a positive control value of 
1.4  ng/mL, the intra- and interassay CVs were 3.7 and 
8.9%, respectively.
Statistical analysis
Categorical variables are expressed as percentages. Con-
tinuous variables are expressed as means (SD) or medians 
(quartiles Q1–Q3) for normal and non-normal distribu-
tions, respectively. Normal distribution was assessed with 
normal Q–Q plots. Differences between nondiabetic and 
diabetic patients were assessed by Chi-squared test, Stu-
dent’s t test, and Mann–Whitney U test, as required. We 
also assessed differences in the levels of the different bio-
markers between nondiabetic and diabetic patients (sub-
sequent to log transformation) after adjustments for age, 
sex, body mass index, and estimated glomerular filtration 
rate.
We performed two Cox regression analyses, with all-
cause or cardiovascular death as the dependent variable 
and the selected biomarker plus DM plus the interaction 
between the covariate biomarker and DM as independent 
covariables. In the Cox models, to fulfill the assumption 
of linearity of the covariables NT-proBNP, hs-TnT, ST2, 
hs-CRP, galectin-3, and sNEP, we used the logarithmic 
functions of NT-proBNP, hs-TnT, hs-CRP, galectin-3, 
and sNEP; the quadratic term of ST2; and log(hs-TnT). 
Afterwards, Cox regression analyses were performed 
separately for diabetic and nondiabetic patients for each 
biomarker. We used a 1SD increase, calculated jointly 
for the whole cohort, for HR calculations in the five 
logarithm-transformed variables. ST2 analyses were 
performed for every 10  ng/mL change. In patients with 
sNEP levels below the lower range of detection (0.250 ng/
mL), a concentration of 0.249 ng/mL was introduced as 
a continuous variable. Survival curves for all-cause death 
were plotted for nondiabetic and diabetic patients based 
on the best cut-off points of ST2, obtained from AUC. 
As a sensitivity analysis of the 265 diabetic patients with 
all the biomarkers collected, we performed two compre-
hensive multivariable Cox regression analyses with all 
the biomarkers and also clinical variables, again for all-
cause and cardiovascular death. Finally, a simple clinical 
model (age, sex, New York Association functional class, 
left ventricular ejection fraction and estimated glomeru-
lar filtration rate (CKD-EPI equation) was developed and 
discrimination evaluated (AUC) adding each one of the 
biomarkers and the best short combinations. Statistical 
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analyses were performed with SPSS 15 (SPSS Inc., Chi-
cago, IL, USA) and version 2.11.1 of the R statistical 
package (Foundation for Statistical Computing, Vienna, 
Austria). Two-sided p < 0.05 was considered significant.
Results
We included 1069 consecutive ambulatory HF patients 
in the study. Table  1 lists the clinical characteristics 
of the total cohort and statistical differences based 
on the presence or absence of DM. The mean age was 
66.2  ±  12.8  years, and 72% of the patients were men. 
The predominant HF etiology was ischaemic heart dis-
ease (51%), and the mean LVEF was 33.5  ±  13.3%. In 
total, 385 patients (36%) had DM. Upon inclusion, 198 
and 151 patients were receiving oral antidiabetic medi-
cation and insulin, respectively; 39 patients were taking 
both. During follow-up, these numbers increased to 285 
and 241, respectively (166 patients were receiving both 
treatments). As expected, many of the clinical charac-
teristics were different between nondiabetic and diabetic 
patients (Table 1). For example, serum concentrations of 
five of the eight studied biomarkers were higher in dia-
betic patients: NTproBNP (p = 0.07), hs-TnT (p < 0.001), 
galectin-3 (p  <  0.001), cystatin-C (p =  0.001), and sTfR 
(p = 0.005) (Table 1). After adjustment for age, sex, body 
mass index, and estimated glomerular filtration rate, 
NTproBNP (p  =  0.01), hs-TnT (p  <  0.001), and sTfR 
(p < 0.05) levels remained significantly higher in diabetic 
patients, while levels of galectin-3 (p =  0.1), cystatin-C 
(p = 0.86), hs-CRP (p = 0.62), sNEP (p = 0.61), and ST2 
(p = 0.28) were no longer significantly different between 
the two groups.
During a mean follow-up period of 4.9  ±  2.8  years 
(6.6 ± 2.3 years for patients who did not die in the follow-
up period), 534 patients died. Of the patients who died, 
284 died from cardiovascular causes: 137 of progressive 
HF, 67 of sudden death, 26 of acute myocardial infarc-
tion, four of stroke, six during cardiovascular procedures, 
and 31 of other cardiovascular causes. One hundred and 
ninety-six patients died of noncardiovascular causes, 
while the cause of death was unknown in 54 patients. As 
expected, both all-cause and cardiovascular mortality 
were higher in diabetic patients (57.7 vs. 45.6%, p < 0.001 
and 34.8 vs. 24.2%, respectively; p < 0.001).
There were no interactions between the majority of the 
biomarkers and DM with respect to prediction of risk of 
all-cause or cardiovascular death (Fig. 1). However, ST2 
significantly interacted with DM for all-cause (p = 0.02) 
and cardiovascular (p = 0.03) death.
Figure  1 shows the HRs and 95% CIs of Cox regres-
sion analyses for each biomarker for nondiabetic and 
Table 1 Clinical characteristics and  treatment during  fol-
low-up categorised according to diabetic status
Data presented as mean ± SD, median (interquartile range), or N (%)
ACEI angiotensin converting enzyme inhibitor, ARB angiotensin II receptor 
blocker, BMI body mass index, COPD chronic obstructive pulmonary disease, 
CRT cardiac resynchronisation therapy, DM diabetes mellitus, eGFR estimated 
glomerular filtration rate (CKD-EPI equation), HF heart failure, hs-CRP high-
sensitivity C reactive protein, hs-TnT high-sensitivity troponin T, ICD implantable 
cardiac defibrillator, LVEF left ventricular ejection fraction, MRA mineralcorticoid 
receptor antagonists, NYHA New York Heart Association, NTproBNP N-terminal 
pro-brain natriuretic peptide, STfR soluble transferrin receptor
Characteristics Nondiabetic
N = 684
DM
N = 385
p value
Age, years 65.3 ± 14 67.8 ± 10.3 0.002
Men 501 (73.2) 267 (69.4) 0.17
White 677 (99) 384 (99.7) 0.18
Aetiology <0.001
 Ischaemic heart failure 310 (45.3) 235 (61) <0.001
 Dilated cardiomyopathy 80 (11.7) 43 (11.2) 0.94
 Hypertensive 60 (8.8) 37 (9.6) 0.50
 Valvular 81 (11.8) 36 (9.4) 0.15
 Alcohol 48 (7) 10 (2.6) 0.001
 Other 105 (15.3) 24 (6.2) 0.01
HF duration, months 24 (3–70.8) 24 (4–71.6) 0.77
LVEF, % 33.7 ± 13.3 33.1 ± 13.2 0.61
NYHA class III–IV 154 (22.5) 107 (27.8) 0.54
Hypertension 392 (44.2) 286 (74.3) <0.001
Peripheral arteriopathy 75 (11) 82 (21.3) <0.001
COPD 125 (18.3) 56 (14.5) 0.12
BMI, Kg/m2 26.4 (23.9–29.7) 27.6 (25–31.2) <0.001
Heart rate, bpm 71.4 ± 14.6 73 ± 13.5 0.07
Blood pressure, mmHg 125.8 ± 22.2 128.8 ± 23.4 0.04
eGFR, mL/min/1.73 m2 57.7 ± 27.2 50.9 ± 24.9 <0.001
Sodium, mmol/L 139.2 ± 3.4 137.9 ± 8.4 <0.001
Haemoglobin, g/dL 13.1 ± 1.9 12.5 ± 1.8 <0.001
Biomarkers
 NTproBNP, ng/L 1183 (494–2679) 1469 (629–3697) 0.007
 hs‑TnT, ng/L 19.1 (9.1–36.4) 28.6 (14.7–44.6) <0.001
 ST2, ng/mL 38 (30.3–49.9) 38.6 (31.3–52.6) 0.23
 hs‑CRP, mg/L 3.2 (1.3–8.3) 4.2 (1.4–8.7) 0.28
 Galectin‑3, ng/mL 15.6 (11.8–21.5) 17.4 (14–23.4) <0.001
 Cystatin‑C, mg/L 1.28 (1.04.–1.73) 1.42 (1.13–1.89) 0.001
 Neprilysin, ng/mL 0.63 (0.38–1.23) 0.66 (0.39–1.09) 0.71
 STfR, mg/L 3.6 (2.8–4.6) 3.9 (3–4.9) 0.005
Treatments, N (%)
 ACEI or ARB 617 (90.2) 335 (87.0) 0.11
 Beta‑blocker 611 (89.3) 353 (91.7) 0.21
 MRA 378 (55.3) 245 (63.6) 0.008
 Loop diuretic 605 (88.5) 365 (94.8) 0.001
 Digoxin 262 (38.3) 151 (39.2) 0.77
 CRT 55 (8) 32 (8.3) 0.88
 ICD 90 (13.2) 50 (13) 0.94
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diabetic patients, both for all-cause (left) and cardiovas-
cular (right) death. In diabetic patients, the HRs for ST2 
were 1.27 (95% CI 1.16–1.40, p  <  0.001) and 1.23 (95% 
CI 1.09–1.39, p =  0.001) for all-cause and cardiovascu-
lar death, respectively. In nondiabetic patients, the HRs 
for ST2 were 1.53 (95% CI 1.35–1.73, p < 0.001) and 1.64 
(95% CI 1.31–2.05, p  <  0.001) for all-cause and cardio-
vascular death, respectively. Survival curves for diabetic 
and nondiabetic patients based on the best cut-off of ST2 
values are shown in Fig. 2. Divergence of the curves and 
HRs are also mildly higher in nondiabetic than in dia-
betic patients. Table  2 shows, in a sensitivity analysis, 
multivariable Cox regression analyses performed in the 
265 diabetic patients with all the biomarker studied. Hs-
TnT, ST2 and cystatin-C remained statistically associated 
with all-cause death and hs-TnT, ST2 and galectin-3 with 
cardiovascular mortality. Finally, Discrimination analysis 
using a simple clinical model and the studied biomark-
ers and the best short combinations of them, according 
also to the previous multivariable analysis are shown in 
Table  3. Results show that the combination of two bio-
marker such as hs-TnT and ST2 significantly improved 
discrimination, as assessed by confidence intervals.
Discussion
The present study was performed in a large cohort of 
ambulatory patients with HF and included a long-term 
follow-up. The three main findings were as follows. First, 
the levels of most of the biomarkers that we studied were 
higher in diabetic patients; however, when we adjusted 
for confounders, only NT-proBNP, hs-TnT, and sTfR were 
significantly higher in diabetic patients. Secondly, inde-
pendent of the finding stated above, we did not find any 
differences between nondiabetic and diabetic patients for 
most of the biomarkers with respect to prognostic value 
for all-cause and cardiovascular mortality. Finally sST2 
which was a significantly predictor for both all-cause 
and cardiovascular death in both diabetic and nondia-
betic subjects was associated with an appreciably higher 
risk in the nondiabetic patients. This biomarker together 
Fig. 1 HRs and 95% CIs for biomarkers based on the presence or absence of DM, and statistical significance of the interaction covariate for DM and 
the biomarkers. A 1SD increase was used for HR calculations in the logarithm‑transformed variables NTproBNP, hs‑TnT, hs‑CRP, cystatin‑C, galectin‑3, 
STfR, and neprilysin. ST2 analyses were performed for every 10 ng/mL change. Age was included as a covariate in the neprilysin analysis. For the 
quadratic form of ST2: p = 0.02 for all‑cause death and p = 0.03 for cardiovascular death. For the quadratic form of log(hs‑TnT): p = 0.82 for all‑cause 
death and p = 0.1 for cardiovascular death. Interactions between DM and the quadratic form of ST2: p = 0.02 for all‑cause death and p = 0.03 for 
cardiovascular death. Interactions between DM and the quadratic form of log(hs‑TnT): p = 0.82 for all‑cause death and p = 0.1 for cardiovascular 
death. hs‑CRP, high‑sensitivity C reactive protein; hs‑TnT, high‑sensitivity troponin T; NTproBNP, N‑terminal pro‑brain natriuretic peptide; STfR, soluble 
transferrin receptor
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Fig. 2 Cox regression survival curves for all‑cause mortality relative to the best cut‑off point of ST2. a Nondiabetic patients; b diabetic patients
Table 2 Multivariable Cox regression analyses for risk of all-cause and cardiovascular death in diabetic patients
All p values are those found in the last step remaining in the model. p value for (ST2)2: All-cause mortality, p = 0.005; Cardiovascular mortality, p = 0.08. p value for 
(log-hs-TnT)2: All-cause mortality, p = 0.02; Cardiovascular mortality, p = 0.007
ACEI angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker, eGFR estimated glomerular filtration rate (CKD-EPI equation), hs-CRP high-
sensitivity C reactive protein, hs-TnT high-sensitivity troponin T, LVEF left ventricular ejection fraction, NYHA New York Heart Association, NTproBNP N-terminal pro-
brain natriuretic peptide, STfR soluble transferrin receptor
a Log-transformed and per 1 SD
b Per 10 ng/mL
All‑cause death Cardiovascular death
HR 95% CI p value HR 95% CI p value
Age 1.04 1.02–1.06 <0.001 1.02 1.00–1.05 0.04
Female sex 0.77 0.54–1.11 0.16 0.70 0.43–1.13 0.15
Ischemic etiology of HF 0.90 0.64–1.27 0.56 0.98 0.63–1.52 0.92
LVEF 1.01 1.00–1.03 0.02 1.02 1.00–1.03 0.03
NYHA functional class 1.83 1.37–2.44 <0.001 1.75 1.18–2.58 0.005
eGFR 1.00 0.99–1.02 0.55 1.00 0.99–1.01 0.69
Hemoglobin 1.02 0.96–1.13 0.72 1.01 0.89–1.15 0.85
ACEI or ARB treatment 0.78 0.47–1.28 0.32 0.76 0.39–1.49 0.42
β‑blocker treatment 0.93 0.52–1.65 0.79 1.06 0.49–2.30 0.89
NT‑proBNPa 1.15 0.93–1.43 0.21 1.24 0.93–1.65 0.15
Hs‑TnTa 1.32 1.08–1.63 0.008 1.53 1.13–2.05 0.005
ST2b 1.20 1.09–1.33 <0.001 1.18 1.03–1.34 0.01
Neprilysina 0.99 0.85–1.16 0.91 0.99 0.80–1.22 0.94
Galectin‑3a 1.12 0.92–1.37 0.25 1.27 1.03–1.57 0.02
Cystatin‑Ca 1.31 1.11–1.54 0.001 1.22 0.82–1.82 0.32
Hs‑CRPa 0.91 0.78–1.06 0.24 1.05 0.85–1.29 0.65
STfRa 1.06 0.88–1.28 0.54 1.06 0.83–1.34 0.65
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with hs-TnT were the only markers that were indepen-
dently associated with both all-cause and cardiovascular 
mortality in the diabetic patients of our cohort. Some of 
the biomarkers that we investigated have been shown in 
previous studies to be predictors of the incidence of car-
diovascular events and prognosis in diabetic patients and 
some of them have also shown to help in distinguishing 
those individuals with a high risk of CV disease among 
diabetic subjects [19]. In elderly patients with DM, NT-
proBNP is a strong independent predictor of short-term 
cardiovascular mortality, including patients without 
preexisting cardiovascular disease [20]. Also, in type 2 
diabetic patients with microalbuminuria but without 
known coronary artery disease, NT-proBNP has been 
shown to be strongly associated with future CV events 
[17]. Moreover, hs-TnT levels in diabetic subjects were 
recently described as the strongest predictor (in addition 
to sST2 and hs-CRP) of short-term outcome in patients 
with stable coronary artery disease [21]. Also in type 2 
diabetic patients, normal hs-TnT level has a high nega-
tive predictive value for future adverse CV events [22]. 
In the present study there were no interactions between 
the majority of the biomarkers and DM with respect to 
prediction of risk of all-cause or cardiovascular death. 
However, ST2 significantly interacted with DM for all-
cause and cardiovascular death being associated with a 
higher risk in nondiabetic compared to diabetic patients. 
Experimental and human studies have suggested rela-
tionships between ST2 and myocardial stretch, fibrosis, 
adverse cardiac remodelling, inflammation, impaired 
haemodynamics, and vascular disease [23]. Indeed, in 
experimental studies ST2 appears to play a pivotal role in 
LV remodeling; this process comprises changes in cardiac 
structure, myocardial composition, myocyte deforma-
tion, and multiple biochemical and molecular alterations 
that impact heart function and reserve capacity [24]. 
The currently available data are insufficient to allow us 
to determine conclusively whether the value of ST2 as 
a marker of cardiac remodelling is different in patients 
with and without diabetes. That is, patients with diabe-
tes may be affected by other variables such as advanced 
glycation end products, inflammatory markers, or micro-
vascular damage that may be involved in the remodel-
ling process and thus could explain the difference in the 
prognostic value of ST2 concentrations between patients 
with and without DM. On the other hand, the source of 
ST2 is not well established; although it is known to be 
produced by both cardiac fibroblasts and cardiomyocytes 
in response to injury or stress, nonmyocardial produc-
tion by endothelial cells has also been suggested [25]. The 
multivariable Cox regression analysis showed that ST2 
together with hs-TnT were the only biomarkers analysed 
in the present study that were independently associated 
with heart failure prognosis (all-cause and cardiovascu-
lar mortality) in diabetic patients. Moreover, the com-
bination of two biomarkers (ST2 together with hs-TnT) 
increased the predictive value of HF prognosis compared 
to what is obtained when only one of them is determined.
Diabetes is widely recognized as a significant risk fac-
tor for the development of HF and is an independent risk 
factor for increased mortality among individuals with HF. 
Indeed, HF is one of the most common initial manifesta-
tion of cardiovascular disease in patients with T2D [3]. 
Thus, it is of clinical interest to investigate whether the 
biomarkers used for assessing the prognosis of heart fail-
ure perform similarly in diabetic and non-diabetic sub-
jects (both with regard to its serum concentrations and 
as to its prognostic value). To our knowledge there are no 
studies to date that have specifically addressed whether 
current predictive biomarkers used in the general popu-
lation with heart failure are also useful in patients with 
diabetes. Our conclusion is that, in our cohort of HF 
patients, biomarkers used in the general population to 
predict the clinical course of heart failure are also useful 
in patients with diabetes. In these patients, among all the 
biomarkers analysed only hs-TnT and ST2 were indepen-
dently associated with both all-cause and cardiovascular 
mortality. The use of a combination of biomarkers (mul-
timarker strategy) in predicting the risk of death seems 
Table 3 C-statistics for risk of all-cause and cardiovascular 
death in diabetic patients
Clinical model: age, sex, New York Heart Association functional class, left 
ventricular ejection fraction, and estimated glomerular filtration rate (CKD-EPI 
equation); hs-CRP high-sensitivity C reactive protein, hs-TnT high-sensitivity 
troponin T, NTproBNP N-terminal pro-brain natriuretic peptide, STfR soluble 
transferrin receptor
All‑cause death Cardiovascular 
death
AUC 95% CI AUC 95% CI
Clinical model 0.733 0.683–0.783 0.644 0.589–0.707
 +NT‑proBNP 0.751 0.702–0.800 0.666 0.606–0.624
 +Hs‑TnT 0.790 0.735–0.844 0.671 0.606–0.637
 +ST2 0.790 0.735–0.846 0.646 0.579–0.713
 +Neprilysin 0.733 0.683–0.783 0.648 0.589–0.707
 +Galectin‑3 0.780 0.724–0.835 0.650 0.583–0.716
 +Cystatin‑C 0.781 0.725–0.836 0.647 0.580–0.715
 +Hs‑CRP 0.769 0.710–0.827 0.639 0.571–0.707
 +STfR 0.766 0.707–0.824 0.633 0.565–0.701
 +Hs − TnT + ST2 0.811 0.759–0.863 0.683 0.617–0.748
 +Hs − TnT + ST2 +  
NT‑proBNP
0.810 0.757–0.863 0.690 0.625–0.754
 +Hs − TnT + ST2 +  
cystatin‑C
0.812 0.759–0.864 – –
 +Hs − TnT + ST2 +  
galectin‑3
– – 0.699 0.635–0.763
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to be in diabetic patients as good as in the general popu-
lation with HF [10], improving discrimination, mainly 
when two biomarkers are combined.
Limitations
A limitation of this study is that most of the diagnoses 
of DM were made from clinical records, treatment regi-
mens, and, for some patients, blood chemistry data alone. 
However, most previous diabetes studies used this form 
of data acquisition. Indeed, patients were classified into 
nondiabetic and diabetic subgroups according to their 
baseline diagnosis and no data on new-onset diagnosis 
of DM during follow-up were considered. Additionally, 
we could not assess the impact of diabetes duration as a 
powerful contributing factor in these patients. Although 
our study participants were drawn from the general 
population attending an HF unit, the unit is located at a 
tertiary university hospital and the cohort patients were 
mainly male and of ischaemic aetiology. The great major-
ity had been admitted to a hospital in the previous year 
or had depressed LVEF. Therefore, we cannot disregard 
the possibility of bias due to selection of patients who 
may not necessarily represent the general HF population.
Conclusions
DM has little impact on the predictive power of the HF 
biomarkers NT-proBNP, hs-TnT, galectin-3, hs-CRP, cys-
tatin-C, sTfR, and neprilysin. Only ST2, which had pre-
dictive value in both diabetic and nondiabetic patients, 
was associated with a higher risk in nondiabetic patients.
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